Myocardial Infarction Animal Models & CRO Services

Heart Attack - Myocardial Infarction Animal Models & CRO Services - Preclinical Cardiac Disease Cardiac disease is a major cause of death and disability in the U.S. and worldwide. This is often due to atherosclerosis ("hardening of the arteries") and occlusion of the coronary arteries, leading to myocardial infarction (MI, "heart attack") and its late complications. About 1 million Americans suffer an acute MI each year, accounting for 180,000 deaths. About 5.8 million Americans have chronic congestive heart failure (CHF), most often due to ischemic heart disease and previous MIs.

Biotrofix is highly-experienced in rodent models of myocardial infarction (MI). In these models, the left coronary artery (LCA) is surgically ligated, resulting in low blood flow (ischemia) and death of cardiac tissue supplied by that artery. MI volume is assessed by histological methods. Both permanent and temporary (ischemia/reperfusion) MI models are available. Models of CHF in animals with chronic MI are also available. These models are appropriate for preclinical testing of agents useful for the treatment of MI and chronic CHF.

Home The Company Preclinical Research Services The Team News Publications Contact Us Site Map

Biotrofix is a premier preclinical contract research organization specializing in animal models of CNS, cardiac and vascular disease. With years of experience, both academic, commercial, clients throughout the biotech and pharmaceutical industries, Biotrofix delivers industry-leading preclinical CRO services, including rodent models of acute stroke and stroke recovery, preclinical CRO services for Alzheimer's Disease, transgenic animal models for ALS, as well as CRO services for brain injury, preclinical CRO services for spinal cord injury and related cardiac drug discovery and development.